Investigational Drug Details
| Drug ID: | D181 |
| Drug Name: | Prednisone |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00635 |
| DrugBank Description: | A synthetic anti-inflammatory glucocorticoid derived from [cortisone].[A187463] It is biologically inert and converted to [prednisolone] in the liver.[L10502] Prednisone was granted FDA approval on 21 February 1955.[L10496] |
| PubChem ID: | 5865 |
| CasNo: | 53-03-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |
| Structure: |
|
| InChiKey: | XOFYZVNMUHMLCC-ZPOLXVRWSA-N |
| Molecular Weight: | 358.4281 |
| DrugBank Targets: | Glucocorticoid receptor |
| DrugBank MoA: | Prednisone is first metabolized in the liver to its active form, prednisolone, a glucocorticoid agonist corticosteroid.[L10502] The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.[A187463] Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.[A187463] Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.[A187463] Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.[A187463] High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.[A187463] |
| DrugBank Pharmacology: | Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.[A187463] Prednisone has a short duration of action as the half life is 2-3 hours.[L10502] Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces.[A187463] Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.[A187463] |
| DrugBank Indication: | Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.[L10502] |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L1116 | NCT01750294 | PHASE4 | COMPLETED | YES | 2012-08 | 2016-06-13 | Details |
| L1208 | NCT06608212 | ACTIVE_NOT_RECRUITING | NO | 2024-10-09 | 2025-04-11 | Details | |
| L1783 | NCT00479466 | PHASE2 | TERMINATED | YES | 2007-07 | 2015-09-09 | Details |
| L1995 | NCT03102476 | COMPLETED | NO | 2016-06 | 2018-10-31 | Details | |
| L1999 | NCT02520076 | PHASE1|PHASE2 | COMPLETED | NO | 2015-08 | 2022-05-24 | Details |
| L2525 | NCT00909480 | PHASE4 | COMPLETED | YES | 2009-05 | 2017-03-10 | Details |
| L2564 | NCT00476710 | COMPLETED | NO | 2007-05 | 2015-04-01 | Details | |
| L2577 | NCT01217112 | PHASE2 | COMPLETED | YES | 2010-10 | 2022-10-18 | Details |
| L3223 | NCT01375322 | PHASE4 | COMPLETED | NO | 2007-06 | 2011-06-17 | Details |
| L7038 | NCT00654745 | PHASE4 | COMPLETED | YES | 2008-05 | 2010-07-13 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|